<DOC>
	<DOCNO>NCT01820442</DOCNO>
	<brief_summary>The primary objective study assess lofexidine relate effect QTc ( interval heart rhythm ) subject receive buprenorphine maintenance . The secondary objective study evaluate safety tolerability lofexidine evaluate monitoring pharmacokinetics ( amount drug blood ) , vital sign ( heart rate blood pressure ) adverse event ( side effect ) co-administered buprenorphine ; describe effect opiate withdrawal lofexidine introduce follow 50 % buprenorphine dose reduction , require elicit withdrawal response ; evaluate QTc interaction effect lofexidine compare placebo . The Investigators hypothesize lofexidine know prolong QTc interval , combination drug create additive effect create significant safety concern . The Investigators hypothesize subject able tolerate therapeutic dose lofexidine ( 0.8 mg four time daily ) buprenorphine maintenance dose lower elicit withdrawal .</brief_summary>
	<brief_title>Pharmacokinetic &amp; Pharmacodynamic Interaction Lofexidine Buprenorphine Buprenorphine Maintained Patients</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled multiple ascend dose study assess safety , tolerability , electrocardiographic effect lofexidine 30 buprenorphine-maintained adult subject . The study include Screening Visit , Inpatient Treatment Visit , Follow-Up Visit . Subjects randomize 4:1 ratio receive 4 tablet lofexidine ( 0.2 mg/tablet ) QID 4 tablet match placebo QID . Subjects stable dose total daily sublingual buprenorphine 16-24 mg/day without naloxone ( Suboxone® Subutex® , respectively ) , 16 - 24 mg/day , satisfy inclusion exclusion criterion eligible study . Subjects eligible study encourage begin shift medication dose total daily dose 2 PM anticipation study dose schedule Inpatient Treatment Visit . Subjects receive Suboxone tablet Subutex study enrollment convert Suboxone film inpatient check-in receive Suboxone sublingual film throughout study . Within 21 day Screening Visit , subject report inpatient study facility begin Inpatient Treatment Visit last approximately 11 21 day . This visit include inpatient check-in ( 1 day ) , Buprenorphine Baseline ( 1 day ) , Initial Lofexidine Titration ( 3 5 day ) , 1 2 Lofexidine Plateaus ( 2 4 day ) , Buprenorphine Reduction ( 2 6 day ) Buprenorphine Re-Titration Discharge ( 2 4 day ) . The order step subject proceed Inpatient Treatment Visit vary depend whether subject able titrate high dose lofexidine placebo Initial Lofexidine Titration . The high dose lofexidine ( placebo ) 4 tablet QID ( 0.2 mg lofexidine per tablet placebo ) total daily lofexidine dose 16 tablet ( 3.2 mg placebo ) . During Buprenorphine Baseline phase subject take single daily dose buprenorphine 2 PM . Buprenorphine Baseline Day study assessment begin approximately 7 AM include electrocardiogram ( ECG ) monitoring , blood collection buprenorphine pharmacokinetics , opiate withdrawal assessment ( Clinical Opiate Withdrawal Scale , COWS Short Opiate Withdrawal Scale , SOWS ) . The next day subject proceed Initial Lofexidine Titration phase . Subjects continue use baseline buprenorphine dose . Lofexidine initiate 2 tablet ( 0.4 mg placebo ) QID titrate daily increment single tablet ( 0.2 mg placebo ) QID total daily dose 0.8 mg QID ( placebo ) , tolerate subject . Lofexidine dose escalate daily unless point subject meet protocol-defined dose hold criterion ( describe ) , trigger reduction dose previous high tolerate dose ( 1 tablet dose , 0.2 mg placebo , subject tolerate initial 2 tablet , 0.4 mg placebo ) . Once subject titrate high dose ( ie , 4 tablet QID ) high tolerate dose determine , proceed 2-day Lofexidine Plateau phase continue receive buprenorphine maintenance dose . If subject unable titrate 4 tablet QID ( 0.8 mg placebo ) , subject continue receive high tolerate dose equal increment ( eg , 2 3 tablet QID 8AM , 1PM , 6PM , 11PM ) day plateau . Subjects tolerate 4 tablet QID ( 0.8 mg placebo ) first day receive 4 tablet QID ( 0.8 mg placebo ) accord normal dosing schedule . On second day , lofexidine dosing schedule modify subject receive 1-tablet increase ( ie , 0.2 mg placebo ) 1 PM lofexidine dose ( 5 tablet : 1 mg placebo ) 1-tablet reduction ( 0.2 mg placebo ) subsequent lofexidine dose ( 3 tablet : 0.6 mg placebo ) 2 dos 4 tablet ( 0.8 mg placebo ) total daily dose 16 tablet ( 3.2 mg/day placebo ) . On second day Lofexidine Plateau phase , subject undergo ECG monitoring blood collection buprenorphine lofexidine pharmacokinetics . COWS SOWS assessment perform day Lofexidine Plateau . Subjects titrate daily dose 4 tablet ( 0.8 mg placebo ) QID receive full dose buprenorphine undergo 4-day buprenorphine dose reduction 50 % continue take lofexidine placebo daily dose 16 tablet evaluate effect lofexidine buprenorphine withdrawal sign symptom . These subject complete initial Lofexidine Plateau dose 0.8 mg lofexidine ( placebo ) QID reach COWS 5 great prior fourth day reduce buprenorphine dose administration may proceed early Buprenorphine Re-titration Discharge Investigator 's discretion . If COWS score reach 5 within 4 day , subject proceed Buprenorphine Re-titration Discharge . Subjects unable titrate high lofexidine dose ( 4 tablet : 0.8 mg placebo QID ) receive full dose buprenorphine undergo buprenorphine dose reduction 50 % 6 day continue receive high tolerate dose lofexidine initial titration . On fourth day ( earlier investigator 's discretion base withdrawal response ) , lofexidine titration resume add incremental 1 tablet ( 0.2 mg placebo ) QID previously establish tolerate dose maximum 4 tablet ( 0.8 mg placebo ) QID dose . During subsequent titration attempt lofexidine ( placebo ) dose escalate daily begin fourth day reduction ( earlier base discretion investigator ) unless event subject meet protocol define dose-hold criterion ( describe ) , trigger reduction dose previous high tolerate dose require Lofexidine Plateau procedures describe repeated maintain subject newly reduce buprenorphine dose ( eg , 50 % maintenance dose ) . Subjects unable titrate high lofexidine dose 50 % Buprenorphine Reduction dose titrate Initial Lofexidine Titration repeat Lofexidine Plateau procedure . During Buprenorphine Reduction , COWS SOWS assessment opiate withdrawal perform . On day lofexidine dose increase , holter monitor PK sample do subject titrate way maximum dose lofexidine initial titration period . Following completion Lofexidine Plateau ( repeat necessary ) Buprenorphine Reduction , subject begin Buprenorphine Re-Titration Discharge phase lofexidine placebo discontinue buprenorphine re-titrated start dose ( high low dose relative baseline medically indicate discretion investigator ) . Lofexidine may use treat withdrawal symptom , necessary . Following successful buprenorphine titration completion study assessment , subject discharge inpatient study clinic . Subjects return study clinic follow-up visit 7 day ( ±2 day ) follow clinic discharge safety follow-up adverse event collection . Subjects discharge study time unless medically unstable dose buprenorphine . Subject may medically follow regular interval , determine investigator , subject consider sufficiently stable study discharge . Subjects withdraw consent meet one follow study termination criterion prior completion study withdrawn . Study termination criterion apply pre-dose sit vital sign daily safety ECG reading ( exclude HR ) . Baseline value vital sign ECG reading refer value obtain time subject admit clinic . 1.Cardiovascular event include following* : a. Systolic blood pressure ( SBP ) &lt; 70 mmHg &gt; 20 % baseline value , b. Diastolic blood pressure ( DBP ) &lt; 40 mmHg &gt; 20 % baseline value ( subject asymptomatic , DBP termination criterion &lt; 30 mmHg ) , c. Heart rate &lt; 40 bpm &gt; 20 % baseline value ( subject asymptomatic , HR termination criterion &lt; 30 bpm ) , d. Changes QTcF meet follow criterion : i.QTcF &gt; 500 m female QTcF &gt; 480 m male , ii . QTcF &gt; 25 % baseline value male female , iii . QTcF &lt; 500 m female QTcF &lt; 480 m male persistent ( ie , great 24 hour ) increase QTcF value &gt; 60 m baseline accompany abnormal electrolyte ( ie , potassium sodium ) , e. Absolute QRS &gt; 120 m along 25 % increase baseline , f. Absolute PR &gt; 240 m along 25 % increase baseline , g. Syncope h. Clinically significant arrhythmia ( include telemetry indication ventricular tachycardia , ventricular fibrillation , Torsade de Pointes , 2nd degree AV block ) *ECGs vital sign may repeat appropriate confirm value rule extraneous result . 2.Serious medical problem think relate unrelated study medication . 3.Intercurrent illness medical complication , opinion site investigator , preclude safe administration study medication . At time termination study , subject discontinue lofexidine placebo ; however , may remain inpatient usually 4 day , extension allow deem necessary per Investigator , buprenorphine maintenance dose re-titrated pre-study maintenance dose .</detailed_description>
	<mesh_term>Substance Withdrawal Syndrome</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Lofexidine</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Adult male and/or female , 18 60 year age ( inclusive ) . Receiving buprenorphine maintenance treatment opioid dependence stable total daily dose 1624 mg least 4 week prior checkin Inpatient Treatment Visit . Body mass index ≥ 18 ≤ 35 ( kg/m2 ) . Normal screen result abnormal result deem Investigator clinically insignificant . Able understand willing sign inform consent form ( ICF ) . Females practice adequate birth control nonchildbearing potential . Medically acceptable birth control method study include intrauterine device ( IUD ) ; vasectomize partner ( minimum 6 month ) ; postmenopausal ( least 2 year ) ; surgically sterile ( least 6 month ) ; double barrier ( diaphragm spermicide , condom vaginal spermicide ) ; abstinence ; implant intrauterine hormonal contraceptive use least 6 consecutive month prior study dose throughout study duration ; oral , patch inject hormonal contraceptive vaginal hormonal device ( ie , NuvaRing® ) use least 3 consecutive month prior study dose throughout study duration . Abnormal cardiovascular exam screen randomization , include following* : clinically significant abnormal electrocardiogram ( ECG ) ( eg , significant first degree atrioventricular block , complete leave bundle branch block [ LBBB ] , second third degree heart block , clinically significant arrhythmia , QTcF interval ( machine read ) great 450 msec male great 470 msec female ) heart rate &lt; 55 bpm symptomatic bradycardia systolic blood pressure ( SBP ) &lt; 95 mmHg symptomatic hypotension diastolic blood pressure ( DBP ) &lt; 65 mmHg blood pressure ( BP ) &gt; 155/95 mmHg change orthostatic SBP , DBP , heart rate &gt; 25 % sit value prior history myocardial infarction ( MI ) evidence prior MI ECG history long QT syndrome relative condition history syncopal episode intraventricular conduction delay QRS duration &gt; 120 ms evidence ventricular preexcitation ( eg , Wolff Parkinson White syndrome ) *ECGs vitals may repeat appropriate order confirm value rule extraneous result . History presence significant clinically unstable cardiovascular ( include atrial fibrillation , congestive heart failure , myocardial ischemia , indwell pacemaker ) , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , psychiatric , neurologic , dermatologic disease . History presence degree chronic obstructive pulmonary disease . History suicidal ideation depression require professional intervention include counsel antidepressant medication past 12 month . Positive drug ( urine ) /alcohol ( breath ) test screen checkin exclude buprenorphine . Subjects positive test heroin , tetrahydrocannabinol ( THC ) , benzodiazepine Screening Visit may enrol test negative checkin Inpatient Treatment Visit . Subjects positive test heroin , THC benzodiazepines Screening Visit must sign ICF checkin Inpatient Clinic Visit . Receiving buprenorphine pain management . Positive test human immunodeficiency virus ( HIV ) hepatitis B surface antigen ( HBsAg ) . Subjects positive test hepatitis C antibody ( HCV ) may enrol subject asymptomatic . Estimated creatinine clearance &lt; 80 mL/minute screening ( CockcroftGault formula ) . AST , ALT , alkaline phosphatase &gt; 3.0 x upper limit normal screen checkin . Amylase lipase &gt; 1.5 x upper limit normal screen checkin . Clinically significant outofreference range clinical chemistry value , particular attention potassium , magnesium , calcium . History hypotension . History hypersensitivity allergy clonidine clonidine analogue . Use new prescription medication within 12 day prior checkin . Use overthecounter medication , include herbal product , within 5 day prior checkin . Up 3200 mg per day ibuprofen 2 gram per day acetaminophen allow discretion principal investigator designee . Use drug know affect QTc within 30 day prior checkin ( tobacco buprenorphine exclude ) . Blood donation significant blood loss within 30 day prior checkin . Plasma donation within 7 day prior checkin . Participation another clinical trial within 30 day prior checkin . Females pregnant lactating . Participation prior study lofexidine hydrochloride . Any condition prior therapy , , opinion Investigator , would make subject unsuitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>lofexidine</keyword>
	<keyword>buprenorphine</keyword>
	<keyword>interaction</keyword>
	<keyword>pharmacodynamic</keyword>
	<keyword>ECG</keyword>
	<keyword>QTc</keyword>
</DOC>